



## Nanobiotix 2018 Q4 and annual revenues

Paris, France and Cambridge, Massachusetts, USA, February 28, 2019 – [NANOBIOTIX](#) (Euronext: NANO – ISIN: FR0011341205), a clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, today announces its unaudited revenues for Q4 and the unaudited annual revenues for the year ended December 31, 2018.

### 2018 Revenues

<i>In €</i>	<i>12/31/2018 (12 months)</i>	<i>12/31/2017 (12 months)</i>
<b>Revenue</b>	<b>105,364</b>	<b>251,967</b>
Of which:		
<i>License</i>	-	146
<i>Services</i>	98,734	251,821
<i>Other sales</i>	6,630	-

### Revenue for Q4 2018

<i>In €</i>	<i>Q4 2018</i>	<i>Q3 2018</i>	<i>Q2 2018</i>	<i>Q1 2018</i>
<b>Revenues</b>	<b>10,244</b>	<b>21,816</b>	<b>73,304</b>	-
Of which:				
<i>License</i>	-	-	-	-
<i>Services</i>	3,614	21,816	73,304	-
<i>Other sales</i>	6,630	-	-	-

### Activity and results

In total, Nanobiotix's revenue for the fourth quarter amounted to €10,244.

Most of the revenue generated by the company during this period came from services that Nanobiotix provided to its partners pursuant to its commercial agreements.

Overall, Nanobiotix's annual revenue in 2018 amounted to €105,364.

In October 2018, the positive results of phase II/III in Soft Tissue Sarcoma with NBTXR3 were presented at the European Society of Medical Oncology (ESMO) congress. NBTXR3 is the first radiotherapy enhancer to demonstrate clinically meaningful benefits for patients with locally advanced Soft Tissue Sarcoma compared to radiotherapy alone.


Furthermore, on October 16, 2018, Nanobiotix announced that it had received the first tranche disbursement of 16 million euros as a loan from European Investment Bank. Proceeds will be used to toward the development of NBTXR3 clinical trial in the head and neck cancers and will support Nanobiotix's European go-to-market strategy

**2019 Financial agenda**

Nanobiotix will announce its financial and operating results as follows:

- March 15, 2019 – 2018 Annual results
- April 11, 2019 – Annual General Meeting, Paris, France
- April 30, 2019 – Revenue for Q1
- July 19, 2019 – Revenue for Q2
- September 4, 2019 - Half year results
- October 25, 2019 – Revenue for Q3

**Breakdown of Nanobiotix’s shareholding structure as of December 31, 2018**



\*\*\*

**About NANOBIOTIX:** [www.nanobiotix.com](http://www.nanobiotix.com)

Incorporated in 2003, Nanobiotix is a leading, clinical-stage nanomedicine company pioneering new approaches to significantly change patient outcomes by bringing nanophysics to the heart of the cell.

The Nanobiotix philosophy is rooted in designing pioneering, physical-based approaches to bring highly effective and generalized solutions to address unmet medical needs and challenges.

Nanobiotix’s first-in-class, proprietary lead technology, NanoXray, aims to expand radiotherapy benefits for millions of cancer patients. Nanobiotix’s Immuno-Oncology program has the potential to bring a new dimension to cancer immunotherapies.

Nanobiotix is listed on the regulated market of Euronext in Paris (Euronext: NANO / ISIN: FR0011341205; Bloomberg: NANO: FP). The Company’s headquarters are in Paris, France, with a U.S. affiliate in Cambridge, MA, and European affiliates in Spain and Germany.

## Contact

---

### Nanobiotix

---

**Sarah Gaubert**

Director, Communications & Public Affairs

+33 (0)1 40 26 07 55

[sarah.gaubert@nanobiotix.com](mailto:sarah.gaubert@nanobiotix.com) /

[contact@nanobiotix.com](mailto:contact@nanobiotix.com)

**Noël Kurdi**

Director, Investor Relations

+1 (646) 241-4400

[noel.kurdi@nanobiotix.com](mailto:noel.kurdi@nanobiotix.com) /

[investors@nanobiotix.com](mailto:investors@nanobiotix.com)



---

### Media relations

---

**France - Springbok Consultants****Marina Rosoff**

+33 (0)6 71 58 00 34

[marina@springbok.fr](mailto:marina@springbok.fr)

**United States – RooneyPartners****Marion Janic**

+1 (212) 223-4017

[mjanic@rooneyco.com](mailto:mjanic@rooneyco.com)

## Disclaimer

*This press release contains certain forward-looking statements concerning Nanobiotix and its business. Such forward-looking statements are based on assumptions that Nanobiotix considers to be reasonable. However, there can be no assurance that the estimates contained in such forward-looking statements will be verified, which estimates are subject to numerous risks including the risks set forth in the reference document of Nanobiotix filed with the French Financial Markets Authority (Autorité des Marchés Financiers) under number D.17-0470 on April 28, 2017 (a copy of which is available on [www.nanobiotix.com](http://www.nanobiotix.com)) and to the development of economic conditions, financial markets and the markets in which Nanobiotix operates. The forward-looking statements contained in this press release are also subject to risks not yet known to Nanobiotix or not currently considered material by Nanobiotix. The occurrence of all or part of such risks could cause actual results, financial conditions, performance or achievements of Nanobiotix to be materially different from such forward-looking statements.*

*This press release and the information that it contains do not constitute an offer to sell or subscribe for, or a solicitation of an offer to purchase or subscribe for, Nanobiotix shares in any country. At the moment NBTXR3 does not bear a CE mark and is not permitted to be placed on the market or put into service until NBTXR3 has obtained a CE mark.*